Relevance of 99mTc-MIBI rest uptake, ejection fraction and location of contractile abnormality in predicting myocardial recovery after revascularization

Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy

BACKGROUND

Cardiac magnetic resonance imaging (CMR) is increasingly used to assess patients for myocardial viability prior to revascularisation. This is important to ensure that only those likely to benefit are subjected to the risk of revascularisation.

OBJECTIVES

To assess current evidence on the accuracy and cost-effectiveness of CMR to test patients prior to revascularisation in ischaemic cardiomyopathy; to develop an economic model to assess cost-effectiveness for different imaging strategies; and to identify areas for further primary research.

DATA SOURCES

Databases searched were: MEDLINE including MEDLINE In-Process & Other Non-Indexed Citations Initial searches were conducted in March 2011 in the following databases with dates: MEDLINE including MEDLINE In-Process & Other Non-Indexed Citations via Ovid (1946 to March 2011); Bioscience Information Service (BIOSIS) Previews via Web of Science (1969 to March 2011); EMBASE via Ovid (1974 to March 2011); Cochrane Database of Systematic Reviews via The Cochrane Library (1996 to March 2011); Cochrane Central Register of Controlled Trials via The Cochrane Library 1998 to March 2011; Database of Abstracts of Reviews of Effects via The Cochrane Library (1994 to March 2011); NHS Economic Evaluation Database via The Cochrane Library (1968 to March 2011); Health Technology Assessment Database via The Cochrane Library (1989 to March 2011); and the Science Citation Index via Web of Science (1900 to March 2011). Additional searches were conducted from October to November 2011 in the following databases with dates: MEDLINE including MEDLINE In-Process & Other Non-Indexed Citations via Ovid (1946 to November 2011); BIOSIS Previews via Web of Science (1969 to October 2011); EMBASE via Ovid (1974 to November 2011); Cochrane Database of Systematic Reviews via The Cochrane Library (1996 to November 2011); Cochrane Central Register of Controlled Trials via The Cochrane Library (1998 to November 2011); Database of Abstracts of Reviews of Effects via The Cochrane Library (1994 to November 2011); NHS Economic Evaluation Database via The Cochrane Library (1968 to November 2011); Health Technology Assessment Database via The Cochrane Library (1989 to November 2011); and the Science Citation Index via Web of Science (1900 to October 2011). Electronic databases were searched March-November 2011.

REVIEW METHODS

The systematic review selected studies that assessed the clinical effectiveness and cost-effectiveness of CMR to establish the role of CMR in viability assessment compared with other imaging techniques: stress echocardiography, single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Studies had to have an appropriate reference standard and contain accuracy data or sufficient details so that accuracy data could be calculated. Data were extracted by two reviewers and discrepancies resolved by discussion. Quality of studies was assessed using the QUADAS II tool (University of Bristol, Bristol, UK). A rigorous diagnostic accuracy systematic review assessed clinical and cost-effectiveness of CMR in viability assessment. A health economic model estimated costs and quality-adjusted life-years (QALYs) accrued by diagnostic pathways for identifying patients with viable myocardium in ischaemic cardiomyopathy with a view to revascularisation. The pathways involved CMR, stress echocardiography, SPECT, PET alone or in combination. Strategies of no testing and revascularisation were included to determine the most cost-effective strategy.

RESULTS

Twenty-four studies met the inclusion criteria. All were prospective. Participant numbers ranged from 8 to 52. The mean left ventricular ejection fraction in studies reporting this outcome was 24-62%. CMR approaches included stress CMR and late gadolinium-enhanced cardiovascular magnetic resonance imaging (CE CMR). Recovery following revascularisation was the reference standard. Twelve studies assessed diagnostic accuracy of stress CMR and 14 studies assessed CE CMR. A bivariate regression model was used to calculate the sensitivity and specificity of CMR. Summary sensitivity and specificity for stress CMR was 82.2% [95% confidence interval (CI) 73.2% to 88.7%] and 87.1% (95% CI 80.4% to 91.7%) and for CE CMR was 95.5% (95% CI 94.1% to 96.7%) and 53% (95% CI 40.4% to 65.2%) respectively. The sensitivity and specificity of PET, SPECT and stress echocardiography were calculated using data from 10 studies and systematic reviews. The sensitivity of PET was 94.7% (95% CI 90.3% to 97.2%), of SPECT was 85.1% (95% CI 78.1% to 90.2%) and of stress echocardiography was 77.6% (95% CI 70.7% to 83.3%). The specificity of PET was 68.8% (95% CI 50% to 82.9%), of SPECT was 62.1% (95% CI 52.7% to 70.7%) and of stress echocardiography was 69.6% (95% CI 62.4% to 75.9%). All currently used diagnostic strategies were cost-effective compared with no testing at current National Institute for Health and Care Excellence thresholds. If the annual mortality rates for non-viable patients were assumed to be higher for revascularised patients, then testing with CE CMR was most cost-effective at a threshold of £20,000/QALY. The proportion of model runs in which each strategy was most cost-effective, at a threshold of £20,000/QALY, was 40% for CE CMR, 42% for PET and 16.5% for revascularising everyone. The expected value of perfect information at £20,000/QALY was £620 per patient. If all patients (viable or not) gained benefit from revascularisation, then it was most cost-effective to revascularise all patients.

LIMITATIONS

Definitions and techniques assessing viability were highly variable, making data extraction and comparisons difficult. Lack of evidence meant assumptions were made in the model leading to uncertainty; differing scenarios were generated around key assumptions.

CONCLUSIONS

All the diagnostic pathways are a cost-effective use of NHS resources. Given the uncertainty in the mortality rates, the cost-effectiveness analysis was performed using a set of scenarios. The cost-effectiveness analyses suggest that CE CMR and revascularising everyone were the optimal strategies. Future research should look at implementation costs for this type of imaging service, provide guidance on consistent reporting of diagnostic testing data for viability assessment, and focus on the impact of revascularisation or best medical therapy in this group of high-risk patients.

FUNDING

The National Institute of Health Technology Assessment programme.

Prognostic value of myocardial perfusion-gated SPECT in patients with ischemic cardiomyopathy

BACKGROUND

There are no extensive series in which risk stratification of patients with ischemic cardiomyopathy (IC) is based on their rest and exercise and scintigraphic characteristics. The purpose of our study was to analyze rest and exercise myocardial perfusion-gated SPECT variables for prognosis in patients with ischemic IC.

METHODS AND RESULTS

Prospective cohort study. A study was performed in 167 patients with IC who consecutively underwent rest myocardial perfusion-gated SPECT. In addition, stress SPECT was performed on 137 of these patients. During an average follow-up of 2.3 +/- 1.2 years, cardiac mortality (CM) was 17.4%. Independent predictors of CM in rest-gated SPECT were the positive criteria for myocardial viability (P = 0.027; Hazard risk, HR: 5.1; 95% CI: 1.2-21.4). In the 137 patients who underwent stress-gated SPECT, predictors were scintigraphic criteria for viability plus ischemia (P = 0.026; HR: 3.6; 95% CI: 1.16-11.2) and exercise duration < or = 5 minutes (P = 0.04; HR: 2.7; 95% CI: 1.01-7.36). Coronary angiography variables, performed in 111 patients, did not significantly modify the prognostic value of non-invasive testing.

CONCLUSION

Myocardial perfusion-gated SPECT improves prognostic stratification of patients with IC.

[Predictors of improved left ventricular systolic function after surgical revascularization in patients with ischemic cardiomyopathy]

INTRODUCTION AND OBJECTIVES

Although it is known that the presence of myocardial viability predicts an increase in ejection fraction after revascularization in patients with ischemic cardiomyopathy, little is known about other predictive factors. The aim of this study was to identify variables that can predict an increase in ejection fraction after coronary revascularization surgery in patients with ischemic cardiomyopathy and a viable myocardium.

METHODS

The study included 30 patients (mean age 61.6 [11] years, one female) with ischemic cardiomyopathy (ejection fraction <or=40%) who fulfilled criteria for myocardial viability. All underwent ECG-gated single-photon emission computed tomography before and after surgery.

RESULTS

An increase in ejection fraction >or=5% occurred after surgery in 17 of the 30 patients (56.6%). These patients were characterized by the presence of left main coronary artery disease (P< .004), a large number of grafts (P< .03), a high perfusion summed difference score (P< .012), a low end-diastolic volume (P< .013), and a low end-systolic volume (P< .01). An end-systolic volume <148 mL and a summed difference score >or=4 gave the best predictive model (P=.001, R2=0.73) for an increase in ejection fraction.

CONCLUSIONS

In patients with ischemic cardiomyopathy and a viable myocardium, the main determinants of an increase in ejection fraction after revascularization surgery were low levels of left ventricular remodeling and myocardial ischemia.

Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings

BACKGROUND

Left ventricular ejection fraction (LVEF) is a significant predictor of morbidity and death. The nuclear summed rest score (SRS) measures myocardial perfusion defects and provides prognostic information, but its effects on long-term outcomes are not fully established. Moreover, information regarding the potential interaction between these 2 covariates is limited. The purpose of this study was to determine whether the mortality risk associated with LVEF is the same across all values of SRS in a population undergoing evaluation for ischemic heart disease.

METHODS AND RESULTS

We examined 3,187 patients who underwent cardiac catheterization and perfusion single photon emission computed tomography imaging with a maximum follow-up of 8.1 years and median follow-up of 3.1 years. Cox proportional hazards modeling showed that increasing nuclear SRS and decreasing LVEF were independently associated with a higher long-term mortality rate, with a clinically significant interaction between them (P = .032). Patients with a normal LVEF and a high SRS (greater perfusion abnormality) have a prognosis similar to those with a reduced LVEF.

CONCLUSIONS

Resting perfusion studies provide prognostic information for long-term survival and significantly impact the interpretation of mortality risk associated with changes in LVEF. Patient prognostication, risk stratification, and future research using these variables should take this interaction into account.

The role of myocardial perfusion imaging in special populations: women, diabetics, and heart failure

Cardiovascular disease and its manifestations remain a major worldwide public health problem. Despite significant advances in diagnosis and treatment, coronary artery disease remains the leading cause of death of men and women in the developed world. Early and accurate diagnosis of coronary artery disease is crucial if men and women are to have improved outcomes. The continuous and dramatic growth in the field of nuclear cardiology during the past 2 decades has accounted for its central role in the clinical evaluation of patients with known or suspected coronary heart disease. The development of electrocardiogram-gated single photon emission tomography has facilitated the expansion of nuclear cardiology studies from the evaluation of myocardial perfusion alone to the evaluation of both perfusion and ventricular function data in a single study. Myocardial perfusion imaging with electrocardiogram-gated single photon emission tomography, with its ability to provide information about the physiologic significance of coronary stenosis, left ventricular function, and risk assessment of patients with coronary artery disease, is ideally suited for the diagnostic and prognostic evaluation of the patient who is at high to intermediate risk for ischemic heart disease.

Clinical characteristics and referral pattern of patients with left ventricular dysfunction and significant coronary artery disease undergoing radionuclide imaging

BACKGROUND

Many observational studies that predict patient outcomes have examined the use of myocardial perfusion imaging results. However, a referral pattern for radionuclide testing could bias these analyses and should be determined. These patients may also differ with regard to the extent of coronary artery disease (CAD). All of these differences must be incorporated into proper outcomes examinations. We sought to identify the nuclear perfusion imaging referral pattern for patients with left ventricular (LV) dysfunction and significant CAD.

METHODS AND RESULTS

Patients with LV dysfunction and CAD (n = 2951) meeting our inclusion criteria were compared by receipt or absence of radionuclide perfusion testing within 6 months before or after angiography. Pearson chi2 and Kruskal-Wallis analyses were used to examine differences in baseline characteristics and catheterization results, whereas logistic regression modeling was applied to predict nuclear imaging referral before and after catheterization. Precatheterization nuclear cohort patients were more likely to be minority patients (odds ratio [OR], 1.34; P =.0083) with previous cardiac revascularization (OR, 2.27; P =.0001), Charlson comorbidity index greater than 1 (OR, 1.146; P =.0091), and heart failure symptoms (OR, 1.62; P =.0001) than those without imaging. They were less likely to have a myocardial infarction (OR, 0.464; P =.0001). After catheterization, the nuclear patients were more likely to have had congestive heart failure (OR, 1.452; P =.0019), a myocardial infarction (OR, 1.353; P =.0371), an ejection fraction lower than 30% (OR, 1.058; P =.0002), and prior revascularization (OR, 1.880; P =.0001). In addition, they had fewer diseased vessels (OR, 0.731; P =.0001).

CONCLUSIONS

Bias exists in nuclear referral for patients with LV dysfunction and significant CAD and must be considered when interpreting observational studies on this topic.

Regional wall motion and wall thickening visual scores from gated SPECT in anterior and infero-lateral myocardial infarctions

BACKGROUND

The relationship between the visual scores for wall motion (WM) and wall thickening (WT) of different left ventricular regions in patients with anterior and infero-lateral myocardial infarctions was evaluated using gated SPECT.

METHODS

Ninety consecutive patients (79 men and 11 women; mean age 56 +/- 9 years) with previous myocardial infarction (33 anterior and 57 infero-lateral) were included. Left ventricular volumes and ejection fractions (EFs) were calculated from quantitative rest gated SPECT 99mTc tetrofosmin images by using the QGS automatic algorithm. Global and regional (anterior, septal, inferior and lateral) wall motion and wall thickening scores were calculated by consensus of three experienced observers.

RESULTS

The correlation between EFs and wall motion and wall thickening scores was better for WM scores in anterior (r=0.904, P<0.0001) than infero-lateral infarctions (r=0.674, P<0.0001). Correlation between wall motion and wall thickening scores was also better for anterior (r=0.898, P<0.0001) than for infero-lateral infarctions (r=0.750, P<0.0001). Except in septal regions, WT scores of the different regions were higher than WM scores (P<0.05) but the statistical significance was higher (P<0.001) in inferior and lateral regions of infero-lateral infarctions.

CONCLUSION

Visual global wall motion and wall thickening scores obtained by gated SPECT showed good correlation between them and with the EF, but differences were observed between regional wall motion and wall thickening, especially in inferior and lateral regions of patients with infero-lateral infarctions.

Myocardial perfusion scintigraphy: the evidence

This review summarises the evidence for the role of myocardial perfusion scintigraphy (MPS) in patients with known or suspected coronary artery disease. It is the product of a consensus conference organised by the British Cardiac Society, the British Nuclear Cardiology Society and the British Nuclear Medicine Society and is endorsed by the Royal College of Physicians of London and the Royal College of Radiologists. It was used to inform the UK National Institute of Clinical Excellence in their appraisal of MPS in patients with chest pain and myocardial infarction. MPS is a well-established, non-invasive imaging technique with a large body of evidence to support its effectiveness in the diagnosis and management of angina and myocardial infarction. It is more accurate than the exercise ECG in detecting myocardial ischaemia and it is the single most powerful technique for predicting future coronary events. The high diagnostic accuracy of MPS allows reliable risk stratification and guides the selection of patients for further interventions, such as revascularisation. This in turn allows more appropriate utilisation of resources, with the potential for both improved clinical outcomes and greater cost-effectiveness. Evidence from modelling and observational studies supports the enhanced cost-effectiveness associated with MPS use. In patients presenting with stable or acute chest pain, strategies of investigation involving MPS are more cost-effective than those not using the technique. MPS also has particular advantages over alternative techniques in the management of a number of patient subgroups, including women, the elderly and those with diabetes, and its use will have a favourable impact on cost-effectiveness in these groups. MPS is already an integral part of many clinical guidelines for the investigation and management of angina and myocardial infarction. However, the technique is underutilised in the UK, as judged by the inappropriately long waiting times and by comparison with the numbers of revascularisations and coronary angiograms performed. Furthermore, MPS activity levels in this country fall far short of those in comparable European countries, with about half as many scans being undertaken per year. Currently, the number of MPS studies performed annually in the UK is 1,200/million population/year. We estimate the real need to be 4,000/million/year. The current average waiting time is 20 weeks and we recommend that clinically appropriate upper limits of waiting time are 6 weeks for routine studies and 1 week for urgent studies.